AstraZeneca Farxiga gets USFDA fast track designation for heart failure

The grant comes after AstraZeneca made strides last month towards its goal of adding heart failure to the conditions that can be treated by Farxiga, putting it ahead of a rival treatment from Eli Lilly.

New Delhi: AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development of its diabetes drug Farxiga to reduce the risk of deadly heart attacks in some patients.

The British drugmaker said FDA’s grant was also for the use of Farxiga to reduce the worsening of heart failure in adult patients with HFrEF and HFpEF subtypes of heart failure.

Farxiga, already approved as a treatment for type-2 diabetes, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.

Also Read: AstraZeneca gets USFDA fast track status for development of diabetes drug Farxiga